Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $91.55
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month […]
More Stories
Financial Survey: Hut 8 (NASDAQ:HUT) and Integrated Ventures (OTCMKTS:INTV)
Hut 8 (NASDAQ:HUT – Get Free Report) and Integrated Ventures (OTCMKTS:INTV – Get Free Report) are both finance companies, but...
Analysts Set HCA Healthcare, Inc. (NYSE:HCA) PT at $391.27
HCA Healthcare, Inc. (NYSE:HCA – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seventeen...
MarketWise (NASDAQ:MKTW) and Definitive Healthcare (NASDAQ:DH) Head to Head Review
Definitive Healthcare (NASDAQ:DH – Get Free Report) and MarketWise (NASDAQ:MKTW – Get Free Report) are both small-cap medical companies, but...
Alkermes plc (NASDAQ:ALKS) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the...
Insider Selling: Palo Alto Networks, Inc. (NASDAQ:PANW) EVP Sells $21,564,000.00 in Stock
Palo Alto Networks, Inc. (NASDAQ:PANW – Get Free Report) EVP Lee Klarich sold 120,000 shares of the stock in a...
Hewlett Packard Enterprise (NYSE:HPE) Receives Average Recommendation of “Moderate Buy” from Analysts
Hewlett Packard Enterprise (NYSE:HPE – Get Free Report) has received an average recommendation of “Moderate Buy” from the fourteen brokerages...